突发!和黄医药引进的重磅品种,宣布全球范围退市

健识局
Mar 10

3月9日,益普生发布公告,在全球所有市场,自愿撤回抗癌药物他泽司他的所有适应症。他泽司他是全球首个问世的EZH2抑制剂,2020年凭借加速批准在美国上市。突然全球撤回,是因为该药可能引发继发性血液恶性肿瘤。全球所有市场都撤回,当然也包括中国。目前,国家医保局已发布公告,撤销他泽司他片在全国各省级医药采购平台挂网,并移出商保目录。同时,和黄医药也公告,将启动撤市及产品召回,并对产品采取锁库措施,暂停...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10